M
Mikkel Porsborg Andersen
Researcher at Aalborg University
Publications - 46
Citations - 756
Mikkel Porsborg Andersen is an academic researcher from Aalborg University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 27 publications receiving 337 citations.
Papers
More filters
Journal ArticleDOI
Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial.
Henning Bundgaard,Johan S Bundgaard,Daniel Emil Tadeusz Raaschou-Pedersen,Christian von Buchwald,Tobias Todsen,Jakob B Norsk,Mia Pries-Heje,Christoffer Rasmus Vissing,Pernille B Nielsen,Ulrik C Winsløw,Kamille Fogh,Rasmus Bo Hasselbalch,Jonas H Kristensen,Anna Ringgaard,Mikkel Porsborg Andersen,Nicole Bakkegård Goecke,Ramona Trebbien,Kerstin Skovgaard,Thomas Benfield,Henrik Ullum,Christian Torp-Pedersen,Kasper Iversen +21 more
TL;DR: This randomized controlled trial investigates whether recommending surgical mask use when outside the home reduces wearers' risk for SARS-CoV-2 infection in a setting where masks were uncommon and not among recommended public health measures.
Journal ArticleDOI
Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study.
Kristian Kragholm,Mikkel Porsborg Andersen,Thomas A. Gerds,Jawad H. Butt,Lauge Østergaard,Christoffer Polcwiartek,Matthew Phelps,Charlotte Andersson,Gunnar Gislason,Christian Torp-Pedersen,Lars Køber,Morten Schou,Emil L. Fosbøl +12 more
TL;DR: Men with Covid-19 infection have >50% higher risk of all-cause death, severe Covid -19 infection, or ICU admission than women, and the excess risk was not explained by age and comorbidities.
Journal ArticleDOI
Cardiovascular comorbidities as predictors for severe COVID-19 infection or death.
Matthew Phelps,Daniel Mølager Christensen,Thomas A. Gerds,Emil L. Fosbøl,Christian Torp-Pedersen,Morten Schou,Lars Køber,Kristian Kragholm,Charlotte Andersson,Charlotte Andersson,Tor Biering-Sørensen,Tor Biering-Sørensen,Helle Collatz Christensen,Mikkel Porsborg Andersen,Gunnar Gislason,Gunnar Gislason +15 more
TL;DR: The results showing only modest effects of CVDs on increased risks of poor COVID-19 outcomes are important in allowing public health authorities and clinicians to provide more tailored guidance to cardiovascular patients, who have heretofore been grouped together as high risk due to their disease status.
Journal ArticleDOI
All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study.
Jawad H. Butt,Emil L. Fosbøl,Thomas A. Gerds,Thomas A. Gerds,Charlotte Andersson,Kristian Kragholm,Tor Biering-Sørensen,Julie Andersen,Mathew Phelps,Mikkel Porsborg Andersen,Gunnar Gislason,Christian Torp-Pedersen,Lars Køber,Morten Schou +13 more
TL;DR: In this paper, the authors investigated mortality rates, overall and according to location, in patients with established cardiovascular disease before, during, and after lockdown measures in Denmark and found that the overall, in-hospital, and out-of-hospital mortality rate in 2020 before lockdown was significantly lower compared with the same period in 2019 [adjusted incidence rate ratio (IRR) 0.87, 95% CI 0.83-0.93, respectively].
Journal ArticleDOI
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Maurizio Sessa,Maurizio Sessa,Annamaria Mascolo,Rikke Nørmark Mortensen,Mikkel Porsborg Andersen,Giuseppe M.C. Rosano,Annalisa Capuano,Francesco Rossi,Gunnar Gislason,Gunnar Gislason,Gunnar Gislason,Henrik Enghusen-Poulsen,Christian Torp-Pedersen +12 more
TL;DR: To compare the hazard of all‐cause, chronic obstructive pulmonary disease (COPD) and heart failure (HF) hospitalization in carvedilol vs. metoprolol/bisoproll/nebivolol users with COPD and concurrent HF from 2009 to 2012, and to evaluate the use and persistence in treatment of these β‐blockers, their impact on the risk of COPD‐related hospitalization, and the factors important for their selection.